Malignant Pleural Mesothelioma (MPM) Market
In 2017, the therapeutic market of Malignant Pleural Mesothelioma in the seven major markets (i.e the United States, EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan) was USD 290 million. The total incident cases of Malignant Pleural Mesothelioma in the 7MM was 11,431 in 2017. The incident cases of Malignant Pleural Mesothelioma in the United Kingdom and the United States were found to be 2,495 and 2,627 respectively. Some of the key companies in the Malignant Pleural Mesothelioma (MPM) Market include Trizell, AstraZeneca, Hoffmann-La Roche, Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, Boehringer Ingelheim Limited, Pfizer, Merck KGaA, Sumitomo Dainippon Pharma, Bayer, ImmunoGen, MorphoSys, TCR2 Therapeutics, Kissei Pharmaceutical, Targovax, Atara Biotherapeutics, Bellicum Pharmaceuticals, Takeda and many others. For more details on Malignant Pleural Mesothelioma Market, visit: https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-market
22 views • 1 slides